Navigation Links
Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Date:1/16/2013

Las Vegas (PRWEB) January 16, 2013

Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, is proud to announce the relaunching of their website. The revised website includes new information regarding the company's platform technology and development programs.

The interactive website provides a user-friendly platform for interested parties to gather information regarding Convoy Therapeutics’ innovative platform technology and its various uses in enabling the penetration of macromolecules and retention of small molecules in the skin for a wide variety of cosmetic and therapeutic uses.
“The revamped website offers comprehensive information regarding Convoy’s ground-breaking technology and how it can be applied in a variety of uses in cosmetic and therapeutic applications,” says Dr. Robert Davis, Chief Business Officer of Convoy Therapeutics. “Perhaps more importantly, it shows the incredible healing opportunities possible when combining other therapies with our skin-penetrating technologies.” Convoy Therapeutics’ main objective is to provide a platform for effective and efficient drug, cosmeceutical, or active delivery into the skin. “The website demonstrates the difference between the previous systems of skin delivery and Convoy’s technology,” adds Dr. Davis.

The newly designed website includes diagrams, videos, and slide presentations that visually demonstrate the Convoy technology penetrating the outer layers of the skin, delivering therapeutic macromolecules. Treatment areas include: dermatology, immunology, vaccinations, and cancer. The website also contains information regarding the company's development pipeline including: CY-102, a reformulated Cyclosporine for topical use in treating psoriasis currently in late stage development, and HA-102PH, a topical cosmetic preparation of hyaluronic acid for enhanced skin tone and hydration also in the later development stages.

The website also provides information on Convoy Therapeutics’ acting Executive Management team, its Chief Scientific Advisor and inventor of the technology, Professor Samir Mitragotri, as well as a video by Professor Mitragotri discussing Convoy Therapeutics’ innovative platform technology.

To find out more about Convoy Therapeutics, please visit our new designed website at http://www.convoytx.com, or contact us at (702) 448-1826.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10321618.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):